Enterosys

What Enterosys does

Enterosys is a French Contract Research Organization (CRO) providing preclinical testing services centered on the gut and gut-organ axis. Founded in 2017 and headquartered in Labège (Toulouse area), France, the company operates with a small team (1-10 employees) and serves pharmaceutical, nutraceutical, dermocosmetics, and food & feed companies across Europe. Its core scientific premise is that the gut drives systemic health via interconnected axes (gut-brain, gut-skin, gut-liver, gut-adipose, gut-cardiovascular, gut-microbiota), and it offers both in vitro and in vivo models to evaluate compound effects on these axes for metabolic, neurodegenerative, gastrointestinal, and dermatological disorders.

The company's platform combines proprietary models — most notably a three-compartment gut-skin system that tracks compounds from colonic fermentation through intestinal uptake to keratinocyte response, plus electrochemical and isotonic sensors for enteric nervous system analysis — with a research program on "enterosynes" (gut-derived bioactives such as 12-HETE, galanin, enkephalin, and apelin). Scientific credibility is anchored by co-founder Professor Claude Knauf and a publication record in Nature, Gut, and Cell. Data hosting runs on HDS-certified OVHcloud infrastructure, ensuring compliance for preclinical health data.

Enterosys generates revenue primarily through fee-for-service preclinical contracts with custom project-based pricing, supported by the CIR (Crédit d'Impôt Recherche) accreditation that gives French clients R&D tax credit advantages. Go-to-market is sales-led and event-driven, combining direct consultative engagement, scientific content marketing (blog, Gut Matrix Guide, newsletter), and participation in industry events such as BioFIT and NutrEvent. No funding rounds, named customers, or revenue figures are publicly disclosed.

Name

Enterosys

Legal name

ENTEROSYS S.A.S.

Website

https://enterosys.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Enterosys is a French preclinical Contract Research Organization (CRO) providing in vitro and in vivo gut and gut-organ axis testing services for pharmaceutical, nutraceutical, dermocosmetics, and food & feed companies developing therapies for metabolic, neurodegenerative, gastrointestinal, and dermatological disorders.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAGAAAB

Preclinical CROs (Discovery/Pharmacology/DMPK)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

SECONDARYHLAGAAAL

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Research Organizations (CRO)

Keywords

• Preclinical testing services
• Contract research organization
• Gut-organ axis models
• In vitro gut models
• In vivo gut models

Headquarters

HQ city

Labège

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Preclinical Contract Research Services: Enterosys generates revenue through fee-for-service preclinical testing contracts. The company designs and implements customized experimental protocols adapted to client development objectives across pharmaceutical, nutraceutical, dermocosmetics, and food & feed sectors. Services include screening of potential assets, lead profiling, mechanism of action characterization, therapeutic effect consolidation, and compound repositioning studies.
2. CIR Credit Facilitation: With CIR (Crédit d'Impôt Recherche) accreditation, Enterosys enables French clients to benefit from significant tax advantages on R&D collaborations, effectively reducing the net cost of research services and providing a financial incentive that facilitates contract acquisition.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Enterosys is a Contract Research Organization (CRO) that provides preclinical testing services focused on the gut and gut-organ axis. The company designs customized experimental protocols using both in vitro and in vivo models to evaluate how pharmaceutical, nutraceutical, dermocosmetic, and food & feed compounds interact with the digestive system and interconnected peripheral organs (gut-brain, gut-skin, gut-liver, gut-adipose, gut-cardiovascular, gut-microbiota axes). Services span drug candidate screening, lead profiling, mechanism-of-action characterization, therapeutic effect consolidation, and compound repositioning studies.

Product overview

Enterosys is a Contract Research Organization (CRO) offering a unified portfolio of preclinical testing services centered on the gut and gut-organ axis. The core offering combines in vivo and in vitro models to assess compound effects across multiple biological axes (gut-microbiota, gut-brain, gut-adipose, gut-liver, gut-cardiovascular, gut-skin). The company organizes its services into four therapeutic application areas: Pharmaceuticals Testing, Nutraceuticals Testing, Dermocosmetics Testing, and Food and Feed Testing, each utilizing shared gut-organ preclinical model capabilities. Supporting these is the Gut Matrix Guide resource. The platform serves pharmaceutical, nutraceutical, dermocosmetic, and food/feed companies seeking to evaluate therapeutic potential across gastrointestinal, neurodegenerative, metabolic, and dermatological disorders.

Differentiator

Problem solved

Functional benefit

Products and services

• Gut and Gut-Organs Preclinical Testing Services Integrated preclinical testing services for the gut and gut-organs axis, including assessments of compound effects on the digestive system and interconnected peripheral organs. Designed for pharmaceutical, nutraceutical, dermocosmetic, and food & feed companies.
• In Vivo Models Whole-organism preclinical models for comprehensive, system-level evaluations of therapeutic compounds across gut-organ axes, providing holistic insights into compound effects.
• In Vitro Models Cell-based preclinical models for precise, high-throughput screening of compound effects on intestinal barrier function and immune crosstalk.
• Pharmaceuticals Testing Preclinical testing services for pharmaceutical compounds targeting metabolic, neurodegenerative, dermatologic, and gastrointestinal disorders, including drug candidate screening, lead profiling, and mechanism of action characterization.
• Nutraceuticals Testing Preclinical evaluation of nutraceutical compounds and bioactive ingredients for efficacy, safety, and their effects on gut health and systemic metabolism.
• Dermocosmetics Testing Preclinical testing for dermocosmetic products including the dual-stage gut-to-skin platform, assessing effects through the gut-skin axis and antioxidant capacity.
• Food and Feed Testing Analysis of functional foods and animal feed for their impact on gut health, microbiome composition, intestinal permeability, and inter-organ communication.

Quantifiable outcome

• Identification of enterosynes (12-HETE) modulating ENS activity and glucose metabolism
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Thinkgut Project ConsortiumcoreStrategic or Co-development Partner · 2 May 2022European research collaboration focused on neurodegenerative disorders, gut microbiota composition, and the role of the gut-brain axis in aging. Enterosys participated in the 4th Project Progress Meeting and closing meeting of the Thinkgut project, contributing expertise on gut-organ axis research in the context of neurodegeneration and aging.
• OVHcloudcoreTechnology or IntegrationOVHcloud serves as the data hosting provider for Enterosys' website (www.enterosys.com) and pre-clinical study scientific data. The hosting is ISO 27001 and HDS (Health Data Hosting) certified, with data stored on HDS France infrastructure in Gravelines and Toulouse data centers. No health data are transferred outside the European Economic Area, ensuring GDPR compliance.
• A-Mansia R&D TeamcoreStrategic or Co-development PartnerCollaborative research partnership on Camu Camu extract study published in the journal Metabolites. The partnership demonstrated dose-dependent effects of Camu Camu extract on obesity and metabolic health in preclinical models, with the A-Mansia team contributing to gut microbiota modulation analysis including Akkermansia muciniphila quantification.
• Comm'IN AgencyminorOthersWebsite development partner that created and edited the Enterosys website in 2022. Located at Rue Saint Bruno, 31 000 Toulouse, France. The site has since been revised and enhanced internally by Enterosys.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Evotec: Global preclinical and clinical CRO with significant capabilities in metabolic disease, neuroscience, and integrated pharmacology. Comparable as a broad incumbent offering gut and metabolic preclinical models as part of larger integrated drug discovery programs, often competing for the same pharma R&D budgets.
• Pharmaron: Integrated CRO/CDMO with extensive preclinical in vitro and in vivo pharmacology capabilities across multiple therapeutic areas. Comparable as a broad incumbent offering preclinical testing services at much larger scale, frequently competing for outsourced compound screening and mechanism-of-action studies.
• Mérieux NutriSciences: Food and nutraceutical testing services provider with strong French roots and global coverage. Comparable in the food & feed and nutraceutical testing segment where Enterosys competes for functional food claim validation, though Mérieux offers a much broader analytical portfolio.
• Charles River Laboratories: One of the largest global preclinical CROs offering in vivo and in vitro services across safety assessment, pharmacology, and discovery. Overlaps with Enterosys on preclinical compound testing for pharma clients but serves as a broad incumbent with bundled offerings and global reach that Enterosys cannot match.
• Eurofins Scientific: Global leader in bioanalytical, microbiome, food, and pharmaceutical testing services. Comparable as a broad incumbent offering overlapping preclinical and microbiome testing services; competes with Enterosys on pharma and food & feed clients but at vastly greater scale and geographic reach.

Emerging players

• Microbiome Insights: Specialty microbiome testing and bioinformatic services CRO focused on gut microbiome analysis for academic and industry clients. Comparable as an emerging specialty CRO serving nutraceutical, food, and pharma microbiome research, though with a more bioinformatics-led offering rather than organ-axis physiology.
• Metabolon: Specialty metabolomics CRO providing metabolite profiling for pharma, nutraceutical, and academic clients. Comparable as an emerging specialty CRO that supports gut-organ mechanism-of-action studies and biomarker work overlapping with Enterosys's metabolomic and microbiota read-outs.

Direct peers

• Oncodesign: French preclinical CRO with deep experience in drug discovery and in vivo/in vitro pharmacology. Highly comparable as a France-based specialty preclinical CRO competing for similar French pharma clients, sharing the CIR accreditation angle and a similar client-centered scientific engagement model.
• Inotiv: Preclinical CRO and research models provider focused on in vivo pharmacology, toxicology, and discovery services. Directly comparable as a preclinical CRO offering in vivo and in vitro compound testing for pharma clients with overlapping capabilities in metabolic and GI models.

Regional players

• Biofortis (Mérieux NutriSciences): France-based preclinical and clinical research organization within the Mérieux group, focused on nutrition, microbiome, and functional food studies. Comparable as a French-based specialty CRO serving nutraceutical and food clients with overlapping gut health and microbiome study capabilities.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/enterosyssas

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Enterosys